Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  cabozantinib-s-malate
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 26 for your search:
Start Over
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XL184-301, NCT00704730
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XL184-307, 2012-001834-33, NCT01605227
A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XL184-308, NCT01865747
A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XL184-202, NCT00596648
Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XL184-201, NCT00704288
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XL184-203, NCT00940225
Study of Multiple Doses and Regimens of XL184 (Cabozantinib) in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XL184-205, NCT01068782
Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: UMCC 2011.069, HUM00052320, NCT01428219
Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib on Bone Metastases in Patients With Castrate Resistant Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Status: Closed
Age: Not specified
Sponsor: Other
Protocol IDs: 12-1031, NCI-2012-00677, NCT01599793
Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or In Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01938, CDR0000741879, ECOG-E1512, E1512, U10CA180820, U10CA021115, NCT01708954
Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02058, GOG-0186K, U10CA180868, U10CA027469, NCT01716715
Cabozantinib for Metastatic Triple Negative BrCa
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 12-431, NCT01738438
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Temporarily closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-00821, CALGB-A091201, A091201, U10CA180821, U10CA031946, NCT01835145
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-00820, CALGB-A031203, A031203, U10CA180821, U10CA031946, NCT01835158
Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-01085, PHII-125, 9303, N01CM00038, P30CA033572, NCT01866410
A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 13-221, XL184-IST26, NCT01954745
Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XL184-001, NCT00215605
Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XL184-002, NCT00960492
Multiple Ascending Dose Study of BMS-907351 (XL184) in Patients With Solid Tumors in Japan
Phase: Phase I
Type: Treatment
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA205-001, NCT01018745
A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XL184-008, NCT01100619
Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 11-005, NCT01347788
Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XL184-014, NCT01553656
XL-184+Abiraterone in Post-Chemo CRPC
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 11-441, NCT01574937
A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: UMCC 2011.105, HUM 62927, NCT01663272
Cabozantinib in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 2 to 18
Sponsor: NCI
Protocol IDs: NCI-2012-01890, CDR0000741914, 13-C-0042, NCI-2013-01571, P121149, COG-ADVL1211, ADVL1211, UM1CA097452, NCT01709435
Start Over